Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic features of 9 cases

Giudice, Ilaria Del; Chiaretti, Sabina; Tavolaro, Simona; Propris, Maria Stefania De; Maggio, Roberta; Mancini, Francesca; Peragine, Nadia; Santangelo, Simona; Marinelli, M; Mauro, Francesca Romana; Guarini, Anna; Foà, Robin

doi:10.1182/blood-2008-12-196568

Cited by 56 publications

(62 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Spontaneous clinical regression of CLL has been previously described in the literature, although a recent study suggested that a residual MBC population remains detectable by flow cytometry or molecular analysis in such patients. 36,37 While the three patients in our study with regression had no evidence of an absolute lymphocytosis, LAD, or splenomegaly at last follow-up, PB specimens were not available to evaluate for the presence of a persistent clonal B-cell population by flow cytometry. Continued follow-up is necessary to determine whether these patients will remain in clinical remission.…”

mentioning

confidence: 97%

Reassessment of small lymphocytic lymphoma in the era of monoclonal B-cell lymphocytosis

Gibson

Swerdlow²,

Ferry³

et al. 2011

Haematologica

View full text Add to dashboard Cite

and Hasserjian RP. Reassessment of small lymphocytic lymphoma in the era of monoclonal B-cell lymphocytosis. Haematologica. 2011; 96:xxx doi:10.3324/haematol.2011.042333 Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors ' final approval; the final version of the manuscript will then appear in print on a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process. Haematologica (pISSN: 0390-6078, eISSN: 1592-8721, NLM ID: 0417435, www.haemato-logica.org) publishes peer-reviewed papers across all areas of experimental and clinical hematology. The journal is owned by the Ferrata Storti Foundation, a non-profit organiza-tion, and serves the scientific community with strict adherence to the principles of open access publishing (www.doaj.org). In addition, the journal makes every paper published immediately available in PubMed Central (PMC), the US National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature. Official Organ of the European Hematology Association Published by the Ferrata Storti Foundation, Pavia, Italy www.haematologica.or

show abstract

mentioning

confidence: 97%

Reassessment of small lymphocytic lymphoma in the era of monoclonal B-cell lymphocytosis

Gibson

Swerdlow²,

Ferry³

et al. 2011

Haematologica

View full text Add to dashboard Cite

show abstract

“…The hypothesis for a key role of the immune system in combating cancer is further supported by clinical observations on spontaneous regressions of tumor in humans (Bodey, 2002;del Giudice et al, 2009;Oquiñena et al, 2009) and an increased risk of some cancer development in immunodeficient patients (Jagadeesh et al, 2012;Kubica & Brewer, 2012). It has also been shown that a presence of immune cell infiltrates in cancer tissues correlate with a better prognosis (Movassagh et al, 2004;Pagès et al, 2005;Wansom et al, 2012).…”

Section: Introductionmentioning

confidence: 91%

Breaking immunotolerance of tumors: A new perspective for dendritic cell therapy

Roliński¹,

Hus

2014

Journal of Immunotoxicology

View full text Add to dashboard Cite

The use of dendritic cells (DC) in cancer immunotherapy is based on their potent abilities to present antigens, so they can act as 'natural adjuvants' to enhance immunogenicity of tumor antigens and stimulate specific cytotoxic T-cells. Large amounts of DC can be generated from bone marrow, neonatal cord blood, and peripheral blood CD34 þ hematopoietic stem cells, or from peripheral blood monocytes. The DC can then be pulsed with tumor antigens and reinfused. In vitro, antigen-pulsed DC can stimulate allogeneic T-cell proliferation and induction of autologous specific cytotoxic T-cells; in vivo, the cells inhibit the growth of tumors or protect hosts (i.e. mice) from development of inoculated tumors. The results of preliminary clinical trials have shown that DC vaccines are safe and elicit immune responses; however, the rates of clinical responses are low. It has become quite clear that one key reason for unsatisfactory clinical results is tumor-induced immunosuppression. Among the factors contributing to this type of immunosuppression are populations of regulatory cells including: T-regulatory (T reg ) cells, myeloid-derived suppressor cells (MDSC), tumor-associated macrophages (TAM), and DC expressing 2,3-dioxygenase indoleamine (IDO-DC). This review presents an overview of the current understanding about populations of regulatory cells and the most current research efforts directed to overcome immunosuppressive activity due to the tumor microenvironment.

show abstract

“…These T cells express the activating receptor NKG2D, which is able to mediate the lysis of CLL cells expressing NKG2D ligands ("induced self" recognition) (Figure 1). Leukemia cells from most patients lack NKG2D ligands expression and are highly resistant to NK cell-mediated lysis, but NKG2D ligands www.intechopen.com expression may be induced in leukemia cells by treatment with trans-retinoic acid or histone deacetilases (HDACs) inhibitors, rendering leukemia cells susceptible to lysis by immune cells Del Giudice et al, 2009). The expansion of T cells has been associated with a better prognosis of CLL patients, supporting the hypothesis that the increase of T cells observed at diagnosis of CLL patients may be due, at least in part, to the expansion of anti-tumor T cells.…”

Section: Immune Surveillance Of Chronic Lymphocytic Leukemiamentioning

confidence: 99%

“…The natural history of stage A disease is generally indolent or only slowly progressive. However, it is less known that CLL may undergo spontaneous regression (Del Giudice et al, 2009). There are no data about the functional role of the immune system in these remissions; however the activation of immune system has been associated with spontaneous remissions in other types of cancers (Smyth et al, 2006;Swann et al, 2007).…”

Section: Immune Surveillance Of Chronic Lymphocytic Leukemiamentioning

confidence: 99%

Immune Response and Immunotherapy in Chronic Lymphocytic Leukemia

Huergo-Zapico¹,

González-Rodríguez²,

Contesti³

et al. 2012

Chronic Lymphocytic Leukemia

View full text Add to dashboard Cite

Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic features of 9 cases

Cited by 56 publications

References 26 publications

Reassessment of small lymphocytic lymphoma in the era of monoclonal B-cell lymphocytosis

Reassessment of small lymphocytic lymphoma in the era of monoclonal B-cell lymphocytosis

Breaking immunotolerance of tumors: A new perspective for dendritic cell therapy

Immune Response and Immunotherapy in Chronic Lymphocytic Leukemia

Contact Info

Product

Resources

About